Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
出版年份 2021 全文链接
标题
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
作者
关键词
-
出版物
Nature Chemical Biology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-05
DOI
10.1038/s41589-021-00742-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Selective Degradation of CDK6 by a Palbociclib Based PROTAC
- (2019) Sandeep Rana et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
- (2019) Baishan Jiang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
- (2019) Yingyao Zhou et al. Nature Communications
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phenotypical microRNA screen reveals a noncanonical role of CDK2 in regulating neutrophil migration
- (2019) Alan Y. Hsu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia
- (2019) Amer M. Zeidan et al. BLOOD
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Development of selective mono or dual PROTAC degrader probe of CDK isoforms
- (2019) Fei Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- iFLinkC: an iterative functional linker cloning strategy for the combinatorial assembly and recombination of linker peptides with functional domains
- (2019) Alexander Gräwe et al. NUCLEIC ACIDS RESEARCH
- CDK2 suppression synergizes with all-trans-retinoic acid to overcome the myeloid differentiation blockade of AML cells
- (2019) Xuejing Shao et al. PHARMACOLOGICAL RESEARCH
- Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2
- (2018) Meidan Ying et al. BLOOD
- CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss
- (2018) Tal Teitz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- OUP accepted manuscript
- (2018) NUCLEIC ACIDS RESEARCH
- Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
- (2018) Solomon Tadesse et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
- (2017) Calla M Olson et al. Nature Chemical Biology
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- Targeted protein degradation by PROTACs
- (2017) Taavi K. Neklesa et al. PHARMACOLOGY & THERAPEUTICS
- GSA: Genome Sequence Archive *
- (2017) Yanqing Wang et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Proteomic Analysis of eIF5B Silencing-Modulated Proteostasis
- (2016) Xu Jiang et al. PLoS One
- Cyclin-dependent kinase 2 protects podocytes from apoptosis
- (2016) Pauliina Saurus et al. Scientific Reports
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
- (2013) E. I. Zimmerman et al. BLOOD
- Current Chemical Biology Approaches to Interrogate Protein Methyltransferases
- (2012) Minkui Luo ACS Chemical Biology
- Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients
- (2012) Barbara Scappini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cyclin-Dependent Kinase 2 Controls Peripheral Immune Tolerance
- (2012) N. Chunder et al. JOURNAL OF IMMUNOLOGY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- In vivobiological effects of ATRA in the treatment of AML
- (2008) Anita Ryningen et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More